Nowadays diabetes has been paid attention by the society. However, with the prolongation of the disease course, the threat of complications will become greater and greater. Due to long-term changes in blood glucose levels, small retinal vessels in fundus will be damaged, which will lead to severe vision loss. Literature reports that 1/3 of diabetic patients will suffer from diabetic retinopathy. Diabetic macular edema (DME) is one of the most common and serious complications of diabetic retinopathy.
According to professor Xu Xun, deputy director of the ophthalmology branch of the Chinese medical association and head of the fundus oculi department, hyperglycemia in diabetic patients will affect the blood vessels and nerves of the whole body, including the blood vessels and nerves of the fundus oculi. About 1/3 of diabetic patients are accompanied by diabetic retinopathy (DR), and about 1/3 of them will have diabetic macular edema (DME). As of 2017, according to Chinese epidemiological literature reports, theoretically there are about 710,000 clinically significant DME patients among the diagnosed diabetes patients in China. These fundus lesions can cause irreversible effects on patients’ vision, so diabetic patients are high-risk groups for vision damage, and vision management of diabetic macular edema patients should be paid more attention.
What is macular? Why does macular edema appear in diabetic patients?
Each of us has a macula, which is the most sensitive area in the center of our eyes. That is to say, a person’s 1.5 vision is that the macula is at work.
The occurrence of diabetic macular edema (DME) is closely related to the course of diabetes and the severity of diabetic retinopathy. In other words, the longer a person suffers from diabetes, the more likely DME will occur, and the more serious diabetic retinopathy, the more likely DME will occur. Diabetic macular edema is also due to the long-term unstable state of blood glucose level, which causes damage to the retinal vascular system, i.e. improves the permeability of the blood retinal system, thus enhancing the permeability of the blood retina, and liquid accumulation (permeate) enters the macular region, thus causing diabetic macular edema. It is conceivable that diabetic macular edema, once occurring in such a sensitive area of the macula, will seriously affect vision loss.
Why does diabetic macular edema need early treatment?
The occurrence of diabetic macular edema (DME) will cause severe visual deterioration, mainly manifested in dark spots in the central area of the visual field, i.e. patchy blurred visual objects, which are difficult to clearly see the details, including close range and long range; Contrast sensitivity will decrease, the color you see will be dim and faded, and the color of the object you see will change and you will feel dark. Look at the shape of the object changing, sometimes larger than the actual shape, sometimes smaller, straight lines appear wavy or broken in some parts of the field of vision. These symptoms of DME patients will seriously affect the quality of life of the patients, affect the normal working conditions, and bring heavy burden to the family and the whole society.
Diabetic macular edema (DME) can be treated
Until 2012, doctors could only use lasers to treat diabetic macular edema (DME). Although laser therapy can prevent further progress of DME, it cannot restore or improve the vision of DME patients, and it may also lead to retinal damage and other adverse events that further affect vision. Therefore, new treatment methods are urgently needed clinically.
In recent years, with the emergence of anti-VEGF drugs such as Abyssal, local anti-VEGF injection has become the first-line treatment for DME. A survey in the United States shows that 90% of doctors choose anti-VEGF to treat macular edema. In Taiwan area of our country, doctors found through investigation that if diabetic macular edema patients do not carry out effective intervention, once they lose their visual function, they will lose their ability to work first, then their ability to take care of themselves, and bring huge care burden. Therefore, Abhisit, which has a definite curative effect, has been accelerated in Taiwan’s medical insurance.
Anti-VEGF brings visual benefits to DME patients
The treatment of ocular fundus diseases was once the most difficult field in ophthalmology. In recent years, with the progress of technology and drugs, some innovative methods have been applied in our country. According to Professor Dai Hong, Director of Ophthalmology Department of Beijing Hospital, diabetic macular edema (DME) is caused by microvascular exudation and neovascularization in the macular region. Abyssinip’s main goal is to resist and block the neovascular endothelial growth factor protein called VEGF, thus reducing neovascular growth, eliminating DME edema and making the patient’s condition no longer develop. Compared with laser therapy, its greatest advantage is that it can reverse the disease and restore some patients’ lost visual function. Even severe DME can improve one line of vision and improve the quality of life. In addition, anti-VEGF has the advantages of high efficiency and low treatment risk.
Diabetic macular edema (DME) requires early detection and treatment, and anti-VEGF therapy for macular edema, which is injected once a month continuously for the first 5 months, and then examined and injected once every two months (8 weeks). After 12 months of treatment, the treatment interval can be prolonged according to vision and anatomical results. Such treatment can greatly improve the work and life quality of patients.